Systemic lupus erythematosus and vaccination

European Journal of Internal Medicine

Volumn 20, Issue 3, 2009, Pages 236-241

  Millet, Arnaud ^a   Decaux, Olivier ^a   Perlat, Antoinette ^a   Grosbois, Bernard ^a   Jego, Patrick ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Autoimmunity; Lupus; Vaccination

Indexed keywords

ANTHRAX VACCINE; AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; LIVE VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; STEROID; TETANUS TOXOID; TOLL LIKE RECEPTOR; TYPHOID VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANKYLOSING SPONDYLITIS; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; BACTERIAL INFECTION; CAMPYLOBACTER ENTERITIS; CANDIDA; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA NODOSUM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GUILLAIN BARRE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HERPES VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; LISTERIA MONOCYTOGENES; MOLECULAR MIMICRY; MYCOBACTERIOSIS; MYCOSIS; MYELITIS; NEISSERIACEAE INFECTION; NOCARDIOSIS; PARASITOSIS; PLEURAL PAIN; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STEROID THERAPY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; STRONGYLOIDIASIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TOXOPLASMA; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VACCINATION; VASCULITIS; VISCERAL LEISHMANIASIS;

AUTOIMMUNITY; BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; VACCINATION; VIRUS DISEASES;

EID: 64749113365     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.07.017     Document Type: Review

References (51)

1. Nemazee D. Receptor selection in B and T lymphocytes. Annu Rev Immunol 18 (2000) 19-51
2. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (2002) 911-920
3. Wraith D.C., Goldman M., and Lambert P.H. Vaccination and autoimmune disease: what is the evidence?. Lancet 362 (2003) 1659-1666
4. Tishler M., and Shoenfeld Y. Vaccines and autoimmunity. In: Rose N.R., and Mackay I.R. (Eds). The autoimmune disease. Fourth ed. (2006), Elsevier 309-316
5. Wucherpfennig K.W. Mechanisms of the induction of autoimmunity by infectious agents. J Clin Invest 108 (2001) 1097-1104
6. Ang C.W., Jacobs B.C., and Laman J.D. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 25 (2004) 61-66
7. Blank M., Krause I., Fridkin M., Keller N., Kopolovic J., Goldberg I., et al. Bacterial induction of autoantibodies to beta 2-glycoprotein I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 109 (2002) 797-804
8. Hemmer B., Jacobsen M., and Sommer N. Degeneracy in T-cell antigen recognition: implication for the pathogenesis of autoimmune disease. Neuroimmunology 107 (2000) 148-153
9. Fourneau J.M., Bach J.M., van Endert P.M., and Bach J.F. The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol 40 (2004) 1095-1102
10. Panoutsakopoulou V., Sanchirico M.E., Huster K.M., Jansson M., Granucci F., Shim D.J., et al. Analysis of the relationship between viral infection and autoimmune disease. Immunity 15 (2001) 137-147
11. Iriya S.M., Capelozzi V.L., Calich I., Martins M.A., and Lichtenstein A. Causes of death in patients with systemic lupus erythematosus in Sao Paulo, Brazil: a study of 113 autopsies. Arch Intern Med 161 (2001) 1557-1561
12. Noel V., Lortholary O., Casassus P., Cohen P., Généreau T., André M.H., et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 60 (2001) 1141-1144
13. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine 78 (1999) 167-175
14. Alarcon G.S. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, polymyositis/dermatomyositis. Infect Dis Clin North Am 20 (2006) 849-875
15. Ross S.C., and Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 63 (1984) 243-273
16. Garred P., Voss A., Madsen H.O., and Junker P. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 42 (1999) 2145-2152
17. Mitchell S.R., Nguyen P.Q., and Katz P. Increased risk of neisserial infections in systemic lupus erythematosus. Semin Arthritis Rheum 20 (1990) 174-184
18. Petri M., and Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus. A prospective study of the Hopkins lupus cohort. J Rheumatol 19 (1992) 1559-1565
19. Hsieh S.C., Tsai C.Y., Sun K.H., Yu H.S., Tsai S.T., Wang J.C., et al. Decreased spontaneous and lipopolysaccharide stimulated production of interleukin 8 by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Clin Exp Rheumatol 12 (1994) 627-633
20. Boros P., Muryoi T., Spiera H., Bona C., and Unkeless J.C. Autoantibodies directed against different classes of Fc gamma R are found in sera of autoimmune patients. J Immunol 150 (1993) 2018-2024
21. Bermas B.L., Petri M., Goldman D., Mittleman B., Miller M.W., Stocks N.I., et al. T helper cell dysfunction in systemic lupus erythematosus (SLE). Relation to disease activity. J Clin Immunol 14 (1994) 169-177
22. Cunha B.A. Infections in nonleukopenic compromised hosts (diabetes mellitus, SLE, steroids, and asplenia) in critical care. Crit Care Clin 14 (1998) 264-282
23. Duffy K.N., Duffy C.M., and Gladman D.D. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 18 (1991) 1180-1184
24. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
25. Pryor B.D., Bologna S.G., and Kahl L.E. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39 (1996) 1475-1482
26. Kahl L.E. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 21 (1994) 84-86
27. Fox R.A. Disseminated lupus erythematosus: an allergic disease?. Arch Pathol 36 (1943) 311-315
28. Ayvazien L.F., and Badger T.L. Disseminated lupus erythematosus occurring among student nurses. N Engl J Med 239 (1948) 565-570
29. Tudela P., Marti S., and Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B. Nephron 62 (1992) 236
30. Maillefert J.F., Tavernier C., Sibilia J., and Vignon E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al. and the letter by Senécal et al. Arthritis Rheum 43 (2000) 468-469
31. Older S.A., Battafarano D.F., Enzenauer R.J., and Krieg A.M. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum 29 (1999) 131-139
32. Naveau C., and Houssiau F.A. Pneumoccocal sepsis in patients with systemic lupus erythematosus. Lupus 14 (2005) 903-906
33. Battafarano D.F., Battafarano N.J., Larsen L., Dyer P.D., Older S.A., Muehlbauer S., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 41 (1998) 1828-1834
34. Elkayam O., Paran D., Caspi D., Litinsky I., Yaron M., Charboneau D., et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 34 (2002) 147-153
35. Elkayam O., Paran D., Burke M., Zakut V., Ben-Yitshak R., Litinsky I., et al. Pneumococcal vaccination of patients with systemic lupus erythematosus. Effects on generation of autoantibodies. Autoimmunity 38 (2005) 493-496
36. Tarján P., Sipka S., Maródi L., Nemes E., Lakos G., Gyimesi E., et al. No short-term immunological effects of pneumococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol 31 (2002) 211-215
37. MacDonald E., Jarrett M.P., Schiffman G., and Grayzel A.I. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 11 (1984) 306-308
38. Elkayam O., Ablin J., and Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 6 (2007) 312-314
39. O'Neill S.G., and Isenberg D.A. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 15 (2006) 778-783
40. Whitney C.G., Schaffner W., and Butler J.C. Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis 33 (2001) 662-675
41. Temine L., and Dab W. [Pneumococcal vaccination : expected benefits in adults]. Rev Med Interne 28 (2007) 9-15 French
42. Brown M.A., and Bertouch J.V. Rheumatic complications of influenza vaccination. Aust N Z J Med 24 (1994) 572-573
43. Del Porto F., Laganà B., Biselli R., Donatelli I., Campitelli L., Nisini R., et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 24 (2006) 3217-3223
44. Holvast A., Huckriede A., Wilschut J., Horst G., De Vries J.J., Benne C.A., et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 65 (2006) 913-918
45. Kuruma K.A., Borda E.F., Lopes M.H., de Carvalho J.F., and Bonfá E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 16 (2007) 350-354
46. Choffray A., Pinquier L., and Bachelez H. Exacerbation of lupus panniculitis following anti-hepatitis-B vaccination. Dermatology 215 (2007) 152-154
47. Geier D.A., and Geier M.R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38 (2005) 295-301
48. Geier M.R., and Geier D.A. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 22 (2004) 749-755
49. Cooper G.S., Dooley M.A., Treadwell E.L., St Clair E.W., and Gilkeson G.S. Risk factors for development of systemic lupus erythematosus: allergies, infections and family history. J Clin Epidemiol 55 (2002) 982-989
50. Aron-Maor A., and Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 10 (2001) 237-240
51. British Society of Rheumatology (BSR). Vaccination in the immunocompromised person : guidelines for the patient taking immunosuppressants, steroids and the new biologic therapies (2002), BSR. http://www.rheumatology.org.uk/guidelines/clinicalguidelines http://www.rheumatology.org.uk/guidelines/clinicalguidelines